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 ABSTRACT 
Meta-analysis can only compare studies with the same interventions, while a 
network meta-analysis can analyze studies with different interventions. Without medical 
data for direct comparisons, network meta-analysis can utilize existing trials to assess the 
relative efficacy of competing treatments. Three classes of statistical models are proposed 
to perform a network meta-analysis: fixed-effects, random-effects, and mixed-effects 
(meta-regression). The most appropriate model should be selected with the aid of a series 
of statistical tests including I2 statistic for heterogeneity and DIC for model fitness. 
Bayesian network meta-analysis provides pooled effect sizes (odds ratio for dichotomous 
outcome) for each treatment and their 95% probability credible intervals. After a 
systematic literature review, 20 randomized clinical trials of biologic anti-rheumatic 
therapies in combination with methotrexate in rheumatoid arthritis patients were 
identified. Random-effects model was used for ACR20 and ACR70 criteria treatment 
outcome whereas the mixed-effects model was used for ACR50 treatment outcome. 
Based on the analysis, we found that all biologics DMARDs were superior to placebo 
except for ANA in all datasets and RTX in ACR70 dataset. ETN was had the highest 
probability to be the best treatment in all three datasets. CTZ had the highest probability 
to be the second best option in ACR20 and ACR50 datasets, and TCZ held the second 
place in the ACR70 dataset. The rest of the rank probabilities vary by dataset but placebo 
was the lowest ranked option in all datasets. Therefore, despite the limitations of this 
study, the results are consistent with current knowledge that biologic DMARDs are 
superior to placebo and although more research remains to be done, ETN may be the 
most effective option for rheumatoid arthritis.
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PREFACE 
Rheumatoid arthritis is a systemic chronic autoimmune disease that brings 
immense pain and burden to patients and society. Several biologic disease-modifying 
anti-rheumatic drugs (DMARDs) are currently available to control and alleviate the 
symptoms. Treatments for rheumatoid arthritis have undergone considerable clinical 
trials, yet there still remain gaps in our knowledge. Only a few head-to-head trials have 
compared the relative efficacy between treatment options.  
Following the manuscript format, this thesis sought: 
To estimate the relative efficacy of biologic DMARDs from randomized clinical trials 
that measured treatment outcome with American College of Rheumatology improvement 
criteria at 24 weeks in both frequentist and Bayesian network meta-analysis. The results 
of the Bayesian models were included in the manuscript as fifth chapter of the thesis.
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1 INTRODUCTION 
1.1 Randomized Clinical Trials and Meta-Analysis 
In the history of thousands of years of medicine, evidence-based health care 
decision making has never played a bigger role in clinical practice as it is today.1 
Evidence-based health care aims at using the best up-to-date evidence to make decisions 
about individual patient care. Randomized clinical trial, the gold standard for evidence-
based health decision-making, commonly compares one therapeutic intervention with 
placebo or standard care. Randomization is used to make sure that the different treatment 
groups will have the same baseline characteristics to remove confounding. When 
conducting clinical trials, both the patients and the practitioners are blinded to treatment 
group assignment (double-blind) to minimize potential bias. Sometimes, even the 
researchers are masked about group assignment during data analysis phase in order to 
observe the true treatment effects (triple-blind). It is quite common that multiple clinical 
trials are conducted for the same intervention in different scenarios and this is when 
meta-analysis, a statistical analytical method that allows one to combine evidence from a 
series of studies can increase the precision of measurement. It allows us to evaluate 
information across studies in a common framework to reduce uncertainty of efficacy 
evaluation .2,3 Meta-analysis requires clinical trials of the same comparators. Clinical 
trials and standard meta-analysis can only demonstrate efficacy over placebo or standard 
care. They do not reveal evidence about relative head-to-head comparison between 
multiple treatments or therapies. On the other hand, pharmaceutical companies have 
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minimal incentives to conduct gratuitous head-to-head clinical trials that are both time-
consuming and expensive. 
1.2 Network Meta-Analysis 
Even though a few clinical trials have involved more than one intervention, few 
studies have looked at more than two interventions. Driven by the need for relative 
treatment efficacy assessment, advanced methods have been developed to incorporate 
multiple interventions. Unlike standard meta-analysis, which can only incorporate trials 
of one intervention, network meta-analysis can incorporate clinical trials of multiple 
interventions and can estimate the relative efficacy between any pair of interventions. 
With a series of direct comparisons that compare treatment A and B (AB trials) and 
treatment A and C (AC trials), an indirect comparison can be made between treatment B 
and C via the common comparator A. When available evidence includes both direct and 
indirect comparisons of multiple interventions, sometimes even to different comparators, 
a network of evidence is formed hence the name network meta-analysis. We describe the 
comparison between treatment B and C using referent A as a comparison anchored on A. 
As shown in Figure 1, an evidence network can be anchored on one or multiple treatment 
groups and can have both open and close loops.4,5 
 
 
 
 
 
A 
C 
B A 
C 
B A 
C 
B 
D 
E 
 3 
 
Figure 1. Examples of Different Types of Evidence Networks 
For network meta-analysis, randomization stands within but not across included 
clinical trials . Study characteristics and patient demographics between clinical trials 
might differ and could also contribute to the variance of relative effect size estimation.4,6,7 
Potential treatment effect modifiers (”modifiers”) may exist in patient characteristics, 
inclusion and exclusion criteria, study protocol development, study outcome 
measurement, and administrative agency requirement. Modifiers could bias the results of 
indirect comparisons and alter the magnitude and direction of treatment effect 
estimation.7,8 Modifiers can also be referred as study-level covariates or covariates in 
network meta-analysis. 
There are two assumptions for network meta-analysis. The first assumption is the 
similarity assumption, which assumes included studies are similar and the modifiers of 
treatment effects are balanced across included studies. The other assumption is 
consistency assumptions, which requires included studies to be consistent with the direct 
and indirect estimation based on 𝑑𝐴𝐶 and 𝑑𝐴𝐵: 𝑑𝐵𝐶 = 𝑑𝐴𝐶 - 𝑑𝐴𝐵 for direct and indirect 
comparisons.  Discrepancy between the direct and indirect estimations compromises the 
similarity assumption and introduces bias into treatment effect estimation.7,9 When these 
assumptions stand, the relative effect between BC (𝑑𝐵𝐶) can be estimated indirectly given 
relative effect between AC (𝑑𝐴𝐶) and AB (𝑑𝐴𝐵) without a direct BC trials: 𝑑𝐵𝐶 = 𝑑𝐴𝐶 - 
𝑑𝐴𝐵. 
For statistical analysis, network meta-analysis can be conducted in the frequentist 
framework and the Bayesian framework. The frequentist approach provides point 
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estimation and its 95% confidence intervals (CIs) for the true treatment effect. The 
Bayesian network meta-analysis has the advantage of the ability to incorporate previous 
knowledge about the treatment effects in a  prior and provide a posterior probability 
distribution for the effect size and associated 95% credible intervals (CrIs).  Compliance 
with the similarity and consistency assumptions is difficult due to small sample size 
(number of studies in a meta-analysis, not overall number of patients as only summary 
data is available in meta-analyses) and potential sampling error of each included study. 
Furthermore, unknown confounding is difficult remove completely. It is crucial to 
evaluate the heterogeneity in an evidence network. Heterogeneity assessments helps 
researchers to understand the impact of assumption violation.4,10,11 
1.3 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease that is 
responsible for approximately 9 million physician visits and 250,000 hospitalizations in 
the United States every year.12 The resulting swollen and painful joints often lead to 
disabilities, diminished quality of life, and premature mortality.13 Cost-effective 
conventional diseases modifying anti-rheumatic drugs (DMARDs) have served as first-
line therapy to relieve the symptoms. However, patients tend to develop tolerance and 
have diminished response over time. Switching to or additional biologic agents is 
recommended in the event of inadequate response to conventional DMARDs. Biologic 
DMARDs further divide into several classes: (1) tumor necrosis factor inhibitors (TNFi): 
adalimumab (ADA), certolizumab pegol (CTZ), etanercept (ETN), golimumab (GLB), 
and infliximab (IFX); (2) T-cell costimulatory modulato: abatacept (ABT); (3) 
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recombinant human interleukin-1 (IL-1) receptor antagonist: anakinra (ANA); (4) B-cell-
depleting monoclonal antibody: rituximab (RTX); (5) monoclonal antibody to the IL-6 
receptor: tocilizumab (TCZ); and (6) janus kinase inhibitor: tofacitinib (TOF). All these 
drugs have undergone randomized clinical trials against methotrexate for regulatory 
approval but there have been few head-to-head trials to compare the relative efficacy 
among them. 
  
 6 
 
2 METHODOLOGY 
2.1 Literature Review and Data Collection 
A systematic literature review was conducted to collect data from peer-reviewed 
journal articles. A pre-determined search strategy (see Appendix A) was used to search 
for qualifying clinical trials in PubMed electronic databases through January 1999 to 
December 2015. Identified studies were screened based on titles and abstracts followed 
by a full-text review on selected studies. The references of full-text reviewed studies were 
also examined for potential additions. 
Studies included had to meet the following inclusion criteria: (1) the study was a 
multisite randomized clinical trial for biologic therapies of interest; (2) the study was 
conducted in adult human rheumatoid arthritis patients; (3) the study outcome was 
measured with American College of Rheumatology (ACR) criteria at week 24. The 
following exclusion criteria were also applied: (1) the study population included patients 
of other inflammatory diseases such as juvenile arthritis, Crohn’s disease, or psoriatic 
arthritis; (2) the study patients did not receive background MTX; (3) the study did not 
report number of patients with a 50% or 70% improvement in ACR criteria (ACR50 or 
ACR70). 
Study outcome data extracted was the number and percentage of responders to 
treatment based on the ACR criteria at week 24. Treatment outcomes measured in 
ACR20/50/70 were considered as separate datasets and evaluated respectively. Study 
characteristics including authorship, year of publication, and biologic intervention 
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received were extracted from selected papers. Patient demographics including mean age, 
percentage of females, mean disease duration in years, swollen joint count (SJC), tender 
joint count (TJC), C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), 
and percentage of rheumatoid factor positive (RF+) were also extracted from selected 
papers. Means and standard errors were also extracted for continuous patient 
demographics if available. Data extracted for ESR and CRP were converted to the unit of 
mm/h and mg/L respectively if reported in other units. Study covariates were centered at 
their weighted means to make the results more interpretable.  
2.2 Data Cleaning 
In meta-analysis, study-level characteristics, specifically those continuous 
characteristics such as age, duration of disease, and some laboratory measurement,  are 
often reported in the same format among included studies but sometimes various 
measurements are provided due to preference of the authors, different practice patterns, 
and even the year of the publication which makes it difficult to pool the data for analysis.  
First, the same measurement may appear in divergent units of researcher’s choice. For 
example, an important laboratory test for RA patient is the C-reactive protein (CRP) level 
test that has been commonly reported in both mg/L and mg/dL. To pool study data into a 
single model, the data need to be in a universal format and scale. In this scenario, we 
have manually inspected the units of all study-level characteristics and adjusted them 
based on a common unit.  
It is a common practice to use the sample mean and standard deviation to describe 
patient demographics in clinical trials. However, some studies reported other forms of 
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summary data using the median, the range, or the interquartile. Formulas have been 
developed to estimate the mean (?̅?) from the median (m), low and high end of the range 
(a and b), and sample size (n). When the median and range was reported instead of the 
mean, the median served as the best estimator of the mean when the number of patients 
was no smaller than 25 in each treatment arm (n ≥ 25). When there was less than 25 
patients in each arm (n < 25), the mean was estimated by formula:14,15 
?̅? ≈
𝑎 + 2𝑚 + 𝑏4  
Similarly, for studies that reported median (m), first and third interquartile (q1 and q3), 
and sample size (n). The following equation was used to estimate the mean regardless of 
the sample size:14 
?̅? ≈
𝑞1 + 𝑚 + 𝑞33  
Missing data among covariates was defined as not reported due to the authors’ 
choice therefore missing data in this study was unrelated to the actual values of the 
missing data and considered missing at random.  Predictive mean matching approach was 
used to perform multiple imputation on missing values in covariates. Three imputed 
datasets were created for missing values and the results of the three imputed datasets 
were pooled for final treatment effect estimation. 
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2.3 Model Selection 
A series of models have been proposed and utilized for network meta-analysis. 
The models have advanced from the simpler fixed-effects and random-effects models to 
the more complicated mixed-effects models (meta-regression) that allow treatment-by-
covariate interactions. Analyses based on these models have been conducted in both 
frequentist and Bayesian frameworks. 
Fixed-Effects Model 
The basic assumption of a fixed-effect (FE) network meta-analysis model is that 
there is a common effect size shared by all included studies. In other words, the FE model 
assumes homogeneity of effect sizes among selected studies meaning each individual 
study used the same research design, methodology, and measurement. The effect size is 
considered unknown but fixed in this model. This model estimates the true effect size µ 
from a sample of selected studies that only differ from the true value by sampling errors. 
Therefore, the mean of individual study effect sizes serves as an unbiased estimator for µ, 
and the confidence interval of µ could be calculated from standard error of the mean. The 
true effect size µ is shared by all the included studies and each observed treatment effect 
sizes is sampled from a normal distribution with the mean and the variance. In the 
treatment network, the placebo group is the most common comparison group and hence 
selected as the primary reference (treatment A). The treatment outcome investigated in 
this thesis follows a binary distribution (reached specific treatment outcome or not). 
Therefore, with the probability of treatment success pjk for each patient receiving 
treatment k in the jth study, the number of observing rjk treatment success in njk patients 
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follows a binomial distribution.16 The fixed-effects network meta-analysis model can be 
described as:16,17 
rik ~ Binomial(pjk, njk);  logit(pjk) = ƞ𝑗𝑘 
ƞ𝑗𝑘= �
µ𝑗𝑏                                                       
µ𝑗𝑏 + 𝑑𝑏𝑘 =  µ𝑗𝑏 + (𝑑𝐴𝑘 −  𝑑𝐴𝑏)        𝑏=A,B,C,…       if 𝑘 = 𝑏              𝑘=B,C,D,…       if 𝑘 is after 𝑏  
𝑑𝐴𝐴 = 0 
where µ𝑗𝑏 and  ƞ𝑗𝑘 is the study specific treatment effect (log-odds) for treatment b and k 
in the jth study respectively, 𝑑𝑏𝑘 is the fixed relative treatment effect (log-odds ratio) of 
treatment k to treatment b among all treatment b-k comparison studies. Under the 
consistency assumption, the 𝑑𝑏𝑘 can be estimated indirectly through a common 
comparator treatment A (𝑑𝑏𝑘=𝑑𝐴𝑘 −  𝑑𝐴𝑏). 
Random-Effects Model 
While fixed-effects model assumes a single shared effect size for each 
comparison pair  all studies, the random-effect (RE) model assumes that the effect sizes 
of underlying studies follow some statistical distribution.18 With the RE model we aim at 
inference about the distribution of effect sizes of selected studies from a random sample 
of studies.  The model assumes that studies selected for were not exact replications and 
vary beyond sampling error . In other words, included studies were not homogeneous. 
Effect sizes are treated as if they were a random sample of a population effect µ and 
model parameters, usually the mean and the variance, are estimated in order to describe 
µ. In a RE network meta-analysis model, the treatment effects 𝛿𝑗𝑏𝑘 are drawn from a 
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selected distribution (commonly normal distribution) and assigned to the included 
studies. This model assumes that the studies included are different due to study 
characteristics but share the same random-effect variance σ2.  With the same logit 
function as the fixed-effects model, the random-effects model can be described as:16,17 
rik ~ Binomial(pjk, njk);  logit(pjk) = ƞ𝑗𝑘 
ƞ𝑗𝑘= �
µ𝑗𝑏             
µ𝑗𝑏 + 𝛿𝑗𝑏𝑘   𝑏=A,B,C,…       if 𝑘 = 𝑏              𝑘=B,C,D,…       if 𝑘 is after 𝑏  
𝛿𝑗𝑏𝑘 ~ Normal (𝑑𝑏𝑘, σ𝑏𝑘2 ) = Normal (𝑑𝐴𝑘 − 𝑑𝐴𝑏, σ𝑏𝑘2 ) 
𝑑𝐴𝐴 = 0 
where µ𝑗𝑏 and ƞ𝑗𝑘 is the study specific treatment effect (log-odds) for treatment b and k 
in the jth study respectively, 𝛿𝑗𝑏𝑘 is the study specific relative treatment effect (log-odds 
ratio) of treatment k to treatment b in the jth study, 𝑑𝑏𝑘 is the pooled relative treatment 
effect of treatment k to treatment b, and σ𝑏𝑘2  is between-study variance for treatment b-k 
comparison studies.  The pooled relative effect 𝑑𝑏𝑘 can also be estimated indirectly 
through a common comparator treatment A (𝑑𝑏𝑘 = 𝑑𝐴𝑘 − 𝑑𝐴𝑏). 
Correlation is expected in multi-level and multi-arm datasets. In network meta-
analysis, treatment effects estimated by the same study, treatment, research group, and 
clinical trial site are more likely to share some similarity compared with estimation by 
other sources. The random-effects network meta-analysis model assesses clustering 
quantitatively with two variance components 𝜏2 and  . The variance component𝜏2 
represents the amount of heterogeneity in the levels of the inner factor (for example, 
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study ID number). The other variance component 𝜌 represents the corresponding 
correlation coefficient between levels of the inner factor (for example, the three treatment 
arms of one clinical trial). There are several options for the variance structure to model 
correlation in the random-effects model. The compound symmetry (CS) structure 
assumes a single variance component 𝜏2 corresponding to all levels of the inner factor 
and a single correlation coefficient 𝜌 for the correlation between different levels. The 
heteroscedastic compound symmetry (HCS) structure assumes a symmetric structure of 
variance components of 𝜏12, 𝜏22, … and a single correlation 𝜌 for the correlation between 
different levels. The unstructured variance-covariance matrix (UN) structure assumes 
variance components of 𝜏12, 𝜏22, 𝜏32, … and 𝜌12,𝜌13, 𝜌23, … for the combinations of levels 
of inner factor. 
 
Figure 2. Structures of Variance Components in Random-effects Model 
Mixed-Effects Model 
Comparing treatment from different studies directly breaks randomization, which 
makes it difficult to distinguish the effect of study characteristics from treatment effects. 
The mixed-effects (ME) models, also known as meta-regression, include study-level 
treatment effect modifiers (referred as covariates often) and can further evaluate 
modifiers’ contribution to heterogeneity. The modifiers are usually centered at its overall 
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mean to make the results more interpretable. The treatment effect modifier 𝑋𝑗 is 
incorporated in the model via the mean of the distribution of random-effects. With the 
same notations used as above, the mixed-effects model can be described as:16,17 
rik ~ Binomial(pjk, njk);  logit(pjk) = ƞ𝑗𝑘 
ƞ𝑗𝑘 = �
µ𝑗𝑏             
µ𝑗𝑏 + 𝛿𝑗𝑏𝑘                                            𝑏=A,B,C,…       if 𝑘 = 𝑏              𝑘=B,C,D,…       if 𝑘 is after 𝑏  
𝛿𝑗𝑏𝑘 ~ Normal�𝑑𝑏𝑘 + 𝛽𝑏𝑘𝑋𝑗 ,σ𝑏𝑘2 � =  Normal�𝑑𝐴𝑘 − 𝑑𝐴𝑏 + (𝛽𝐴𝑘 − 𝛽𝐴𝑏)𝑋𝑗 ,σ𝑏𝑘2 �     
𝑑𝐴𝐴 = 0 
𝛽𝐴𝐴 = 0 
where µ𝑗𝑏 and ƞ𝑗𝑘 is the study specific treatment effect (log-odds) for treatment b and k 
in the jth study respectively, 𝛿𝑗𝑏𝑘 is the study specific relative treatment effect (log-odds 
ratio) of treatment k to treatment b in the jth study, 𝑑𝑏𝑘 is the pooled relative treatment 
effect of treatment k to treatment b, 𝛽𝑏𝑘 is the pooled effect of the covariate, 𝑋𝑗is the 
matrix of the covariate in the jth study, and σ𝑏𝑘2  is between-study variance for treatment 
b-k comparison studies.  The pooled relative treatment effect 𝑑𝑏𝑘 and covariate effect 𝛽𝑏𝑘 
can be estimated indirectly through a common comparator treatment A (𝑑𝑏𝑘 = 𝑑𝐴𝑘 −
𝑑𝐴𝑏;  𝛽𝑏𝑘 =  𝛽𝐴𝑘 − 𝛽𝐴𝑏). 
Using study-level covariate information may affect the magnitude and the 
direction of the relation between the study outcome and the covariate. Therefore, even 
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though ME models provide information about heterogeneity, one should always be 
cautious when interpreting the results.  
Bayesian Framework 
In frequentist meta-analysis, treatment effects are estimated by weighing 
individual estimates by the inverse of their variance. In complicated situations such as 
network meta-analysis and meta-regression, treatment effect estimation and inference are 
based on maximum likelihood. In the Bayesian framework, model parameters are 
considered as random variables whose uncertainty is quantified with probability. The 
prior probability distribution reflects prior belief about possible values of the parameters. 
Additional information from previous clinical trials, observational studies, and reviews 
can be integrated in models to inform researchers in the form of prior distributions. 
Meanwhile non-informative prior distributions minimize influence of parameters on the 
posterior results when no information is given about model parameters. The likelihood 
represents the probably probability of the data given the value of the parameters. A 
posterior probability distribution of the parameter is obtained by combining the prior 
probability distribution and the likelihood as Bayes’ theorem explains:19,20 
p (parameters | data) = 𝑃 (data | parameters) 𝑃 (parameters)
𝑃 (data)  
                                                 ∝ p (data | parameters) p (parameters) 
The likelihood p (data | parameters) is determined by the study dataset collected. 
The prior p (parameters) is based on current understanding and beliefs about the model 
parameters. In network meta-analysis of multiple treatments, the treatment effect 
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functions have more than one parameter. This makes it almost impossible to obtain exact 
posterior quantities for all parameters.  The Monte Carlo method generates random 
sample values of the parameters from their posterior distributions and approximates all of 
these posterior quantities of interest to an arbitrary degree of precision. For example, in 
order to study parameter 𝜃, we let 𝑦1, … , y𝑛 to be the numerical values of a sample from a 
distribution p(𝑦1, … , y𝑛| 𝜃). A number S of independent and identically distributed 
samples of 𝜃 could be acquired from the posterior distribution p(𝜃|𝑦1, … , y𝑛): 
𝜃(1), … , 𝜃(𝑆) ~ (𝜃|𝑦1, … , y𝑛) 
The empirical distribution of the samples {𝜃(1), … ,𝜃(𝑆)} is known as a Monte Carlo 
approximation to p(𝜃|𝑦1, … , y𝑛). The more 𝜃 sampled, the empirical distribution provides 
a closer approximation to the true density therefore the better the approximation.  
 For complicated multi-parametric models such as network meta-analysis models, 
it is difficult to sample from the joint posterior distribution directly. In such cases, Gibbs 
sampler provides a computationally feasible alternative in which samples are drawn from 
the full conditional distributions of parameters. The Gibbs sampler is an iterative 
algorithm in which all parameters start at an initial value. The algorithm needs to run for 
another number T of iterations. Each parameter is sampled from full conditional and has 
its current value updated at each iteration. The current value of each parameter 𝜃(𝑇) only 
depends on the previous value 𝜃(𝑇−1) and is independent from any other past values 
𝜃(𝑇−2), 𝜃(𝑇−3),…, 𝜃(1). In this so-called Markov chain, the algorithm will converge to the 
true distributions as the number T that goes to up towards infinity, By applying the same 
algorithm to the regular Monte Carlo approximation, the joint posterior distributions of 
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the parameters could be approximated by this Markov Chain Monte Carlo (MCMC) 
method.  
No previous studies have assessed study-level covariates in network meta-
analysis for biologic anti-rheumatic therapies. No prior distributions were used in 
Bayesian network meta-analysis models. No assumptions were made about the treatment 
effects of the biologic therapies from external sources other than the studies included in 
the systematic review. We estimated the posterior distribution with the following non-
informative priors to limit inference to clinical trials data only. 
Model Assessment 
Checking the homogeneity and consistency assumptions are as important as 
analyzing the data.  Heterogeneity test checks whether the studies are evaluating the same 
treatment effect. In network meta-analysis, the Cochran's Q test is still the usual statistic 
for testing heterogeneity which uses the weighted sum of squared differences between 
individual study effect and the overall fixed-effects mean estimation.21 P-values are 
obtained by comparing the statistic with a 𝜒2 distribution with k-(n-1) degrees of freedom 
(where k is the number of studies, and n is the number of treatments compared). The Q-
value can be calculated with the following equations:17,22 
𝑄 =  ∑𝑤𝑖 �𝑦𝑖 −   𝑦𝑤�2  
𝑦𝑤 = 
∑𝑤𝑖𝑦𝑖
∑𝑤𝑖
 
𝑤𝑖 = 
1
𝑠𝑖
2 
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Where 𝑦𝑖 and 𝑠𝑖2 (i = 1,2,3,…,k) are the estimated treatment effects and corresponding 
variances of each included studies, 𝑤𝑖 are weights for each study, and 𝑦𝑤 is the weighted 
fixed-effects mean estimation. The results of Cochrane’s Q test needs to be interpreted 
carefully though, since it has low power when studies have small number of studies 
included. A statistically significant result may indicate heterogeneity, but a non-
significant result does not indicate homogeneity. A p-value of 0.10 is often used instead 
of 0.05.23 On the other hand, Q also has too much power as a test of heterogeneity if the 
number of studies is large. It is important to consider to what extent the results of studies 
are consistent. If confidence intervals for the results of individual studies (generally 
depicted graphically using horizontal lines) have poor overlap, this generally indicates the 
presence of statistical heterogeneity.  
Due to the limitation of the Q-test, the I² statistic which describes the percentage 
of variation across studies that is due to heterogeneity was also used in model 
assessment:22 
I² = 100% ×  [Q - (k - 1)] / Q 
In random-effects models, I2 estimates the percentage of how much of the total 
variability in the effect size estimates (heterogeneity plus sampling variability) attributed 
to heterogeneity among the true effects. In mixed-effects models, I2 estimates the 
percentage of the unaccounted variability (residual heterogeneity plus sampling 
variability) can be attributed to residual heterogeneity. I² is an intuitive and simple 
expression of the heterogeneity of studies. The Good Research Practice guideline of the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
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suggested the following thresholds:  I² < 30% is considered mild heterogeneity, and I² > 
50% is considered notable heterogeneity.17  
The assessment of consistency is a currently popular but yet accomplished field of 
research. The current common practice is to compare the calculated effect size 
estimations from both direct and indirect comparisons respectively for inconsistency. 
Another approach is to use the forest plot to examine the consistency graphically. In the 
Bayesian framework, the posterior density of the direct, indirect, and the network overall 
estimations are plotted together to assess consistency.   
Model Fitness 
Discrepancy assessment of model fitness was conducted for goodness of fit with 
in both frequentist and Bayesian frameworks. The goodness of fit summarizes and 
describes the difference between values observed in datasets and values expected in a 
model in order to help researchers to select the best fitting model. In the frequentist 
framework, the maximum-likelihood approach was used. Akaike information criterion 
(AIC) and Bayesian information criterion (BIC) values were used to assess model fitness 
in the frequentist framework. The model with smaller values of AIC and BIC is a better 
fitting model. In the Bayesian framework, the deviance information criterion (DIC) was 
used to assess goodness of fit. The DIC is hierarchical model selection criteria and is 
particularly useful in Bayesian framework when the posterior distributions of parameters 
were obtained Markov Chain Monte Carlo simulation. Similarly, a smaller value of DIC 
indicates a better model fitness. 
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Analytical Packages 
The analysis was carried out in a freely available open source statistical program 
R. Statistical methods in both frequentist and Bayesian framework are provided via R 
packages.24 R package mice (version 2.24, released November 9, 2015) was used for 
multiple imputation. R package metafor (version 1.9-8, released September 28, 2015) 
was used for the analysis in frequentist framework. In the metaphor package, fixed-
effects and random-effects models could be fit on both arm-based and contrast-based 
data. A number of study-level covariates could be added to the random-effects model for 
meta-regression. R package gemtc (version 0.8, released March 1, 2016) was used for the 
Bayesian analysis. The package gemtc could only include one study-level covariate 
(regressor) in the mixed-effects model. Free Bayesian software JAGS (Just Another 
Gibbs Sampler, version 4.2.0, released February 19, 2016)) was used to form Gibbs 
sampling. 
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3 STUDY DATASET 
3.1 Literature Search Results 
The search strategy identified 1,334 articles (Figure 3). After title and abstract 
review, 1,298 studies were excluded due to the following reasons: (1) the study outcome 
was not measured in ACR criteria (n = 1,104); (2) no study outcome reported at week 24 
(n = 180); (3) the study was conducted for psoriatic arthritis (n=8); (4) other reasons (n = 
6). After full-text review, 16 articles were further excluded due to the following reasons: 
(1) the patients were receiving other concomitant RA treatments other (n=10); (2) the 
study did not have background MTX in combination with the biologics (n=5); (3) the 
clinical trial for toficitanib, an oral biologic agent with different indication from other 
biologics (n=1).  
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Figure 3. Flow Chart of Literature Review and Study Selection Process for Eligible 
Studies 
Abbreviation: ACR = American College of Rheumatology 
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The 20 selected studies included a total of 7,666 patients that received biologic 
DMARDs for rheumatoid arthritis. Treatment arms were balanced within each study 
indicating sufficient randomization. Table 1 shows the study characteristics and patient 
demographics of each study, whereas Table 2 shows the numbers of responders and 
response rates for ACR20/50/70 criteria.25-44 The evidence network is demonstrated in 
Figure 2. Each node represents a biologic therapy. Each edge between nodes represents a 
direct comparison and the width of the edges represents the number of clinical trials 
contributing to the comparison pair. Placebo was the common comparator among all 
included studies. Nineteen studies (95%) were two-armed clinical trials that compared 
one biologic therapy with placebo while one study (5%) was a three-armed trial that 
compared two biologics and placebo. For study covariates, three (15%) studies reported 
the median for all patient demographic covariates; two (10%) studies reported the median 
for ESR and CRP, and two (10%) other studies report the geometric mean for also ESR 
and CRP. Baseline ESR, CRP, and RF+ were missing in the ten (50%), one (5%), and 
two (10%) studies, respectively. Imputed values were analyzed separately before pooling 
model estimations for interpretation. 
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Table 1. Study Characteristics and Baseline Patient Demographics 
 
  
Study (Trial name) Publication Year Intervention
Number of 
patients
Age 
(years)
Female
(%)
Duration
(years) SJC TJC
ESR 
(mm/h)
CRP 
(mg/L)
RF+ 
(%)
ADA 207 56.1 76.3 11 19.3 27.3 NR 18 81.6
Placebo 200 56.1 73 10.9 19 28.1 NR 18 89.5
ADA 67 57.2 74.6 12.2 17.3 28 NR 21 NR
Placebo 62 56 82.3 11.1 16.9 28.7 NR 31 NR
ADA 79 53 81 8.8 16.2 27.8 41.7 16.6 81
Placebo 76 54 84 8.4 16.4 24.3 39.3 16.5 83
ADA 204 52.5 79.4 8.1 16.4 26.7 48.5 17.5 68.2
Placebo 108 53.8 75.9 7.9 16.7 27.3 48 16.1 66.3
CTZ 393 51.4 82.4 6.1 21.7 30.8 43.5 16 79.6
Placebo 199 52.2 83.9 6.2 21.2 29.8 45 16 82.8
CTZ 246 52.2 83.7 6.1 20.5 30.1 NR NR 77.5
Placebo 127 51.5 84.3 5.6 21.9 30.4 NR NR 78.2
CTZ 126 53 72.2 9.4 22.8 29 NR NR 73.8
Placebo 121 55.6 66.1 9.9 22.2 31 NR NR 78.5
ETN 59 48 90 13 20 28 25 22 84
Placebo 30 53 73 13 17 28 36 26 90
GLB 35 57 85.7 8.2 14 28 NR 21 NR
Placebo 35 52 74.3 5.6 13 22 NR 20 NR
GLB 89 52 80.9 4.5 13 26 NR 10 86.5
Placebo 133 52 82 6.5 12 21 NR 8 81.2
IFX 86 56 81 8.4 19 32 NR 31 84
Placebo 88 51 80 8.9 19 24 NR 30 77
IFX 360 53 80 7.8 15 22 NR 16 82.8
Placebo 363 52 83.2 8.4 15 22 NR 12 80.7
ABT 156 49 83.3 7.9 21.3 31.6 49.4 31 87.2
IFX 165 49.1 82.4 7.3 20.3 31.7 47.8 33 84.8
Placebo 110 49.4 87.3 8.4 20.1 30.3 47 27 77.3
ABT 318 51.4 81.4 1.9 15.8 25.4 NR 16 75.5
ADA 328 51 82.3 1.7 15.9 26.3 NR 15 77.4
ABT  115 55.8 75 9.7 21.3 30.8 NR 29 99
Placebo 119 54.7 66 8.9 21.8 29.2 NR 32 90
ABT  433 51.5 77.8 8.5 21.4 31 NR 33 81.8
Placebo 219 50.4 81.7 8.9 22.1 32.3 NR 28 78.5
ANA  250 56 79 11 20.1 26.8 41.5 27 76
Placebo 251 57 75 10 20 24.5 42.9 26 78
RTX 337 51.6 80.4 6.85 19 27.9 NR NR 74.4
Placebo 172 52.16 85.5 7.48 20.9 30.2 NR NR 75
TCZ 205 50.8 85 7.5 19.5 31.9 51.2 26 83
Placebo 204 50.6 78 7.8 20.7 32.8 49.7 24 71
TCZ 398 53.4 82 9.3 17.3 29.3 46.4 23 83
Placebo 393 51.3 83 9 16.6 27.9 46.5 22 82
Maini (ATTRACT) 1999
Westhovens (START) 2006
Weinblatt 1999
Kay 2008
Keystone (GO-FORWARD) 2009
2008
Smolen (RAPID 2) 2009
Choy 2012
2006
Study characteristics Baseline patient demographics
Keystone 2004
Weinblatt (ARMADA) 2003
van Vollenhoven (AUGUST-2) 2011
van Vollenhoven 2012
Keystone (RAPID 1)
Schiff (ATTEST) 2008
Kremer (LITHE) 2011
ABT = abatacept; ADA = adalimumab; ANA = anakinra; CRP = C-reactive protein; CTZ = certolizumab pegol; ESR = erythrocyte sedimenation rate; ETN = etanercept; GLB = golimumab; IFX = infliximab; 
mg/L = milligram  per liter; mm/h = millimeters per hour; NR = not reported;  RF+ = tested positive for rheumatoid factor; RTX = rituximab; SJC = swollen joint count; TCZ = tocilizumab; TJC = tender joint 
count
Cohen 2004
Emery (SERENE) 2010
Smolen (OPTION) 2008
Weinblatt (AMPLE) 2013
Kremer 2003
Kremer 
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Table 2. Treatment Response in ACR Criteria 
 
  
Rate Count Rate Count Rate Count
ADA 207 0.633 131 0.391 81 0.208 43
Placebo 200 0.295 59 0.095 19 0.025 5
ADA 67 0.672 45 0.552 37 0.269 18
Placebo 62 0.145 9 0.081 5 0.048 3
ADA 79 0.710 56 0.380 30 0.180 14
Placebo 76 0.460 35 0.150 11 0.050 4
ADA 204 0.470 96 0.280 57 0.090 18
Placebo 108 0.280 30 0.120 13 0.020 2
CTZ 393 0.588 231 0.371 146 0.214 84
Placebo 199 0.136 27 0.076 15 0.030 6
CTZ 246 0.573 141 0.325 80 0.159 39
Placebo 127 0.087 11 0.031 4 0.008 1
CTZ 126 0.459 58 0.180 23 0.000 0
Placebo 121 0.229 28 0.059 7 0.017 2
ETN 59 0.710 42 0.390 23 0.150 9
Placebo 30 0.270 8 0.030 1 0.000 0
GLB 35 0.600 21 0.371 13 0.086 3
Placebo 35 0.371 13 0.057 2 0.000 0
GLB 89 0.596 53 0.371 33 0.202 18
Placebo 133 0.278 37 0.135 18 0.053 7
IFX 86 0.500 43 0.270 23 0.080 7
Placebo 88 0.200 18 0.050 4 0.000 0
IFX 360 0.580 209 0.321 116 0.140 50
Placebo 363 0.255 93 0.097 35 0.047 17
ABT 156 0.667 104 0.404 63 0.205 32
IFX 165 0.594 98 0.370 61 0.242 40
Placebo 110 0.418 46 0.200 22 0.091 10
ABT 318 0.660 210 0.460 146 0.240 76
ADA 328 0.650 213 0.430 141 0.220 72
ABT  115 0.600 69 0.365 42 0.165 19
Placebo 119 0.350 42 0.118 14 0.017 2
ABT  433 0.679 294 0.399 173 0.198 86
Placebo 219 0.397 87 0.168 37 0.065 14
ANA  250 0.380 95 0.170 43 0.060 15
Placebo 251 0.220 55 0.080 20 0.020 5
RTX 337 0.525 177 0.261 88 0.095 32
Placebo 172 0.233 40 0.093 16 0.052 9
TCZ 205 0.590 121 0.440 90 0.220 45
Placebo 204 0.260 53 0.110 22 0.020 4
TCZ 398 0.570 227 0.320 127 0.120 48
Placebo 393 0.270 106 0.100 39 0.020 8
Treatment responses
ACR20 ACR50 ACR70Sample size
van Vollenhoven 2012
Keystone 2008
Smolen 2009
Keystone 2004
Weinblatt 2003
van Vollenhoven 2011
Smolen 2008
Kremer 2011
Study and year Intervention
Kremer 2006
Cohen 2004
Emery 2010
Schiff 2008
Weinblatt 2013
Kremer 2003
Keystone 2009
Maini 1999
Westhovens 2006
Choy 2012
Weinblatt 1999
Kay 2008
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3.2 Evidence Network 
To improve transparency of the analyses, Figure 5 illustrated the evidence network 
of the frequentist network meta-analysis. As demonstrated in the figure, placebo was the 
common comparator among all included studies and one study compared two 
medications with placebo in the same trial. Each of the nodes with label represented a 
treatment option and the drug’s name. Each of the edges represented a treatment 
comparison and the widths of the edges represented the number of clinical trials 
contributing to the comparison pairs.  
 
Figure 4. Evidence Network of Included Randomized Clinical Trials 
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4 FITTING FREQUENTIST MODELS  
Results of frequentist models are demonstrated in this chapter. Dataset for 
ACR20/50/70 criteria were analyzed respectively. For each dataset, fixed-effects, 
random-effects, and mixed-effects model with selected effect modifiers were fit and 
compared.  
4.1 ACR20 Dataset 
This section summarizes and reports frequentist model results for ACR20 dataset. 
Fixed-effect and random-effects models were fit to the ACR20 dataset with no study 
covariates. Mixed-effects models with covariates reported in Table 1 were fit respectively 
to assess their individual contribution to heterogeneity. Model estimations were reported 
for each model and the most suitable model for this dataset was used to draw conclusions. 
Fixed-Effects Model 
Fixed-effects model was fit to the ACR20 dataset first. Based on model 
estimation (Table 3), all medications demonstrated a significant superiority over placebo 
(degrees of freedom [df] = 12). CTZ showed the best treatment effect among all 
medications under ACR20 criteria, followed by ETN, TCZ, RTX, ADA, GLB, IFX, and 
ABT (in this order). ANA showed the least, but significant superiority over placebo 
among all medications.  
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Table 3. Relative Treatment Effects to Placebo, Frequentist FE Model, ACR20 Dataset 
 
Forest plot of odds ratios (ORs) and associated confidence intervals (CIs) for each 
treatment is displayed in figure 5.  
 
Figure 5. Forest Plot of Treatment Effects, Frequentist FE Models, ACR20 Dataset 
For the test of heterogeneity, the null hypothesis which is there is no significant 
heterogeneity among included studies was rejected (Q [df = 12] = 64.686, p-value < 
0.001). From which I² was calculated as 100% × ([64.686 – 12] / 64.686) = 81.4%. The I2 
Treatment Estimated Coefficient OR p-value
CTZ 1.931 6.899 < 0.001
ETN 1.916 6.794 < 0.001
TCZ 1.324 3.758 < 0.001
RTX 1.295 3.651 < 0.001
ADA 1.288 3.624 < 0.001
GLB 1.235 3.437 < 0.001
IFX 1.111 3.038 < 0.001
ABT 0.785 2.192 < 0.001
ANA 0.781 2.184 0.002
Model degrees of freedome = 12
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statistic indicated that substantial heterogeneity existed in the dataset and 81.4% of the 
total variability in the estimated treatment effects was due to heterogeneity. With 
substantial heterogeneity observed among included studies, the assumption of fixed-
effect model was violated. Therefore, appropriate models should be explored and used to 
interpret the data.  
Random-Effects Model 
Random-effects model was fit to the dataset given its more reasonable 
assumptions. In our dataset, one study was a three-armed study that compared two 
different biologic RA medications with placebo. Some of the medications have been 
studied in multiple clinical trials. Therefore, two levels of grouping variable were 
considered in the random-effects model. Treatment effects estimated with different 
values of the outer grouping variable (study ID) were assumed to be independent, while 
those with the same value of the outer grouping variable shared correlated random effects 
based on the inner grouping variable (treatment group). Compound symmetry (CS) 
structure was used as it produced the best model fit among all structures. Two different 
random-effects models were used to explore the impact of correlation in depth. One 
model estimated 𝜌 based on the dataset while the other preset 𝜌 a value of 0.5.  
Table 4 below shows the relative effects compared to placebo for each treatment 
with a fixed 𝜌 of 0.5 and the forest plot of this model can be found in figure 6. As seen in 
Table 5, the 𝜌 estimated model yield similar results to the other model with a slightly 
better model fitness (discussed later in this thesis). Based on the model estimation, all 
medications except ANA demonstrated a significant superiority over placebo. CTZ was 
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still the most efficacious treatment option among all medications, followed by ETN, 
ADA, TCZ, RTX, GLB, IFX, and ABT (in this order). ANA also showed superiority 
over placebo but the effect was not statistically significant. Compared with the results of 
the fixed-effects model, the random-effects model reported the same directions for 
treatment effects and minor differences in magnitudes. However, it affected the 
significance level of some of the treatment options. Once significant, ANA now has non-
significant superiority over placebo in this model.  
Table 4. Relative Treatment Effects to Placebo, Frequentist RE Model, ACR20 Dataset 
(ρ = 0.5) 
 
Table 5. Relative Treatment Effects to Placebo, Frequentist RE Model, ACR20 Dataset 
(ρ estimated) 
 
Table 4.  Treatment Effects, Frequentist RE Model, ACR20 Dataset (ρ = 0.5)
Treatment Estimated Coefficient OR p-value
CTZ 1.929 6.880 < 0.001
ETN 1.861 6.429 0.008
ADA 1.361 3.899 < 0.001
TCZ 1.337 3.809 < 0.001
RTX 1.286 3.618 0.017
GLB 1.155 3.175 0.009
IFX 1.065 2.902 < 0.001
ABT 0.865 2.375 0.001
ANA 0.777 2.174 0.148
Model degrees of freedome = 12
Treatment Estimated Coefficient OR p-value
CTZ 1.929 6.881 < 0.001
ETN 1.861 6.429 0.008
ADA 1.362 3.902 < 0.001
TCZ 1.337 3.809 < 0.001
RTX 1.286 3.618 0.019
GLB 1.155 3.173 0.010
IFX 1.002 2.725 < 0.001
ABT 0.845 2.328 0.002
ANA 0.777 2.174 0.152
Model degrees of freedome = 12
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Figure 6. Forest Plot of Treatment Effects, Frequentist RE models, ACR20 Dataset, 
ρ=0.5 
Since the same dataset was used as the fixed-effects model and the random-effects 
model acknowledges the existence of heterogeneity, the test of heterogeneity remained 
the same conclusion (Q [df = 12] = 64.195, p-value < 0.001), as expected. I² calculated 
equals to 81.3%. The I2 statistic indicated that substantial heterogeneity existed in the 
dataset and 81.3% of the total variability in the estimated treatment effects was due to 
heterogeneity. Random-effects models showed a profound improvement in model fitness 
(ρ = 0.5 model: AIC = 40.60, BIC = 45.45; ρ estimated model: AIC = 42.55, BIC = 47.88) 
compared with fixed-effects model (AIC = 106.26, BIC = 120.81)). Assigning a value of 
0.5 to the variance components 𝜌 showed a small further improvement. The model fitness 
results also favored the random-effects model over the fixed-effects model. 
 31 
 
 
Mixed-Effects Model 
Meta-regression was conducted to explore covariates’ contribution to 
heterogeneity among results of studies using mixed-effects model. Covariates were 
centered at their overall means to make the results more interpretable. To achieve this, the 
difference between the weighted mean of a covariate and the covariate was fit in the 
model. Each covariate was assessed respectively to assess individual effect. Given the 
same multi-level structure, the same variance components were reported in this model. 
Variance component ρ was fixed to 0.5 in the mixed-effects models. 
Table 6 below shows the results of single-covariate mixed-effects models along 
with the ranked treatment effects based on odds ratios. For the study covariates, none of 
them demonstrated a significant effect on treatment success. Duration of disease had the 
biggest effect (OR = 1.105) and age had the slightest effect (OR = 1.002). Each of the 
odds ratios was close to one suggesting that these covariates had no effects on treatment 
success. For the treatments, similar superiority and significance was observed as well 
with different ranks of treatments. It is worth mentioning that the model with covariate 
duration of disease reported the same for the most and the least efficacious treatment as 
the random-effects model but different ranks in the middle. The models with covariates 
SJC or TJC reported ETN the best treatment while CTZ was constantly the best treatment 
in other models.  
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Table 6. Covariate Assessment and Ranked Treatments, Frequentist ME Model, ACR20 
Dataset 
 
 
 
Table 7. Heterogeneity Comparison, Frequentist Models, ACR20 Dataset 
 
 
Table 8. Model Fitness Comparison, Frequentist ME Models, ACR20 Dataset 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th
Age CTZ ETN ADA TCZ RTX GLB IFX ABT ANA
1.002 6.885*** 6.464* 3.898*** 3.817*** 3.623* 3.163* 2.899** 2.383** 2.157
Female Percentage CTZ ETN ADA TCZ RTX GLB IFX ANA ABT
1.039 7.366*** 5.547* 4.239*** 3.581*** 3.389* 3.115** 2.996*** 2.477 2.463***
Duration of Disease CTZ RTX ETN GLB TCZ ADA IFX ABT ANA
1.105 7.272*** 3.900** 3.840 3.749** 3.581*** 3.206*** 2.909*** 2.608*** 1.665
SJC ETN CTZ GLB ADA TCZ RTX IFX ABT ANA
1.074 6.308** 5.564*** 4.833* 4.306*** 3.881*** 3.389* 3.242*** 2.228** 1.978
TJC ETN CTZ GLB ADA RTX IFX TCZ ANA ABT
1.074 6.484*** 5.928*** 4.307** 4.16*** 3.477* 3.457*** 3.239** 2.591 2.189**
Covariate
OR
Ranked Relative Treatments to Placebo and ORs
Significance level: *** p < 0.001, ** p < 0.01, * p < 0.05 (same below), df = 11 for all ME models
Model Test of (residual) heterogeneity I^2
RE model Q [df = 12] = 64.195, p-value < 0.001 81.3%
ME model with covariate age Q [df = 11] = 63.922, p-value < 0.001 82.8%
ME model with covariate female percentage Q [df = 11] = 60.648, p-value < 0.001 81.9%
ME model with covariate duration of disease Q [df = 11] = 43.510, p-value < 0.001 74.7%
ME model with covariate SJC Q [df = 11] = 53.636, p-value < 0.001 79.5%
ME model with covariate TJC Q [df = 11] = 57.689, p-value < 0.001 80.9%
Model AIC BIC
Random-effects model, ρ fixed to 0.5 40.60 45.45
Mixed-effects model with covariate age 41.78 46.16
Mixed-effects model with covariate female percentage 40.53 44.91
Mixed-effects model with covariate duration of disease 40.04 44.42
Mixed-effects model with covariate SJC 41.25 45.63
Mixed-effects model with covariate TJC 41.11 45.49
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For the test of residual heterogeneity, all the models still demonstrated significant 
residual heterogeneity (Table 7). Statistical heterogeneity is inevitable due to clinical and 
methodological differences in network meta-analysis.45 I2 statistic assesses the impact of 
heterogeneity on the analysis. The mixed-effects models reported similar I2 values to 
random-effects model. The inclusion of covariates of duration of disease had the largest 
impact on I2, which was a decrease of about 6% while other covariates had unnoticeable 
effects on I2. The I2 statistic indicates that over 70% of the variability in treatment effect 
estimation is due to heterogeneity rather than sampling error. Including covariates did not 
improve model fitness as all models reported similar AICs and BICs (Table 8). 
4.2 ACR50 and ACR70 Dataset 
This section summarizes and reports frequentist model results for ACR50 dataset. 
The relative treatment effects and impact of study covariates in the ACR50 and ACR70 
dataset is presented in table 9 and Table 11 respectively. Table 10 and Table 12 present 
the model comparison results for ACR50 and ACR70 dataset.  
In the ACR50 dataset, duration of disease demonstrated significant impact on 
heterogeneity and model fitness. Therefore, inference regarding relative treatment effect 
will be based on the mixed-effects model with covariate duration of disease. CTZ 
appeared to be the most efficacious treatment. ANA again was the least efficacious 
treatment option.  
In the ACR70 dataset, duration of disease and SJC both demonstrated significant 
impact on heterogeneity and model fitness. Therefore, inference regarding relative 
treatment effect will be based on the mixed-effects model with covariate duration of 
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disease. When adjusted for duration of disease, CTZ appeared to be the most efficacious 
treatment, whereas when adjusted for SJC, GLB was the most efficacious treatment. 
However, due to the small number of patients that reached the treatment success in 
ACR70 treatment criteria, the effects of study covariates observed in the ACR70 dataset 
could be by chance. 
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Table 9. Covariate Assessment and Ranked Treatments, Frequentist Models, ACR50 
Dataset 
 
 
Table 10. Heterogeneity and Fitness Comparison, Frequentist Models, ACR50 Dataset 
 
 
Table 11. Covariate Assessment and Ranked Treatments, Frequentist Models, ACR70 
Dataset 
 
Table 12. Heterogeneity and Fitness Comparison, Frequentist Models, ACR70 Dataset 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th
ETN CTZ TCZ ADA GLB RTX IFX ANA ABT
18.53** 6.979*** 4.951*** 4.875*** 4.330*** 3.446*** 3.172*** 2.399* 2.148***
ETN CTZ TCZ ADA GLB IFX RTX ABT ANA
12.66* 6.729*** 5.118*** 4.925*** 4.674** 3.567*** 3.364* 2.619*** 2.367
Age ETN CTZ TCZ GLB ADA RTX IFX ABT ANA
1.096 16.33** 6.682*** 5.556*** 4.563** 4.013*** 3.580* 3.329*** 2.872*** 1.637
Female Percentage ETN CTZ TCZ ADA GLB IFX RTX ABT ANA
1.004 12.48* 6.772*** 5.093*** 4.981*** 4.698** 3.602*** 3.343* 2.638*** 2.397
Duration of Disease CTZ ETN GLB TCZ RTX ADA IFX ABT ANA
1.161** 7.490*** 5.833 5.811*** 4.565*** 3.767*** 3.618*** 3.544*** 3.050*** 1.585
SJC ETN GLB ADA TCZ IFX CTZ RTX ABT ANA
1.148* 12.20** 10.50*** 5.856*** 5.325*** 4.504*** 4.459*** 2.964* 2.343*** 1.971
TJC ETN GLB ADA CTZ IFX TCZ RTX ANA ABT
1.113 12.83** 7.557*** 5.411*** 5.349*** 4.760*** 4.016*** 3.168* 3.089* 2.338***
ME Model
(df = 11)
Model CovariateOR
Ranked Treatments and ORs
FE Model
(df = 12) N/A
RE Model
(df=12) N/A
Model Test of (Residual) Heterogeneity I^2 AIC BIC
FE model Q [df = 12] = 50.215, p-value < 0.001 76.1% 98.06 112.6
RE model Q [df = 12] = 49.156, p-value < 0.001 75.6% 41.11 45.96
ME model with covariate age Q [df = 11] = 48.277, p-value < 0.001 77.2% 41.35 45.73
ME model with covariate female percentage Q [df = 11] = 48.803, p-value < 0.001 77.5% 42.22 46.60
ME model with covariate duration of disease Q [df = 11] = 20.311, p-value = 0.041 45.8% 37.14 41.51
ME model with covariate SJC Q [df = 11] = 29.133, p-value = 0.002 62.2% 39.39 43.77
ME model with covariate TJC Q [df = 11] = 37.131, p-value < 0.001 70.4% 40.32 44.70
1st 2nd 3rd 4th 5th 6th 7th 8th 9th
ETN TCZ CTZ ADA GLB ANA IFX RTX ABT
10.98 8.587*** 8.146*** 6.671*** 4.711* 3.140 2.890* 1.900 1.856
ETN TCZ CTZ ADA GLB IFX ANA ABT RTX
11.48 8.496*** 6.844*** 5.722*** 4.728* 3.443*** 2.950 2.530** 1.831
Age ETN TCZ CTZ GLB ADA IFX ABT RTX ANA
1.127 16.00 9.388*** 7.222*** 4.793* 4.261** 3.177** 2.985** 1.986 1.820
Female Percentage ETN TCZ CTZ ADA GLB IFX ANA ABT RTX
0.961 13.39 9.048*** 7.357*** 5.249*** 4.889** 3.267*** 2.574 2.518*** 1.960
Duration of Disease CTZ TCZ GLB ETN ADA IFX ABT RTX ANA
1.171*** 9.577*** 7.121*** 6.286*** 5.057 4.187*** 3.493*** 2.966*** 2.063 1.930
SJC GLB ETN TCZ ADA IFX CTZ ANA ABT RTX
1.228*** 16.49*** 10.87 9.210*** 7.543*** 5.110*** 4.263*** 2.245 2.188*** 1.516
TJC ETN GLB ADA TCZ IFX CTZ ANA ABT RTX
1.160* 11.68 9.629*** 6.575*** 6.191*** 5.394*** 5.150*** 4.260* 2.177*** 1.685
RE Model
(df=12)
N/A
ME Model
(df = 11)
Model CovariateOR
Ranked Treatments and ORs
FE Model
(df = 12)
N/A
Model Test of (Residual) Heterogeneity I^2 AIC BIC
FE model Q [df = 12] = 29.980, p-value = 0.003 60.0% 91.92 106.5
RE model Q [df = 12] = 30.169, p-value = 0.003 60.2% 50.51 55.36
ME model with covariate age Q [df = 11] = 29.690, p-value = 0.002 63.0% 50.21 54.59
ME model with covariate female percentage Q [df = 11] = 27.628, p-value = 0.004 60.2% 50.33 54.71
ME model with covariate duration of disease Q [df = 11] = 14.659, p-value = 0.199 25.0% 46.04 50.42
ME model with covariate SJC Q [df = 11] = 12.815, p-value = 0.306 14.2% 44.08 48.46
ME model with covariate TJC Q [df = 11] = 18.418, p-value = 0.072 40.3% 47.88 52.26
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MANUSCRIPT 
Bayesian Network Meta-analysis for Biologic Therapies in Rheumatoid Arthritis 
Introduction 
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease with 
substantial burden. The 2013 Nationwide Inpatient Survey estimated that RA was listed 
as the principal diagnosis for 8,115 hospitalizations with total hospital charges of $359 
million.46 In 2007, there were 2.6 physician office visits including 1.9 million visits to a 
specialist.47 The 2005 United States Medical Expenditure Panel Survey (MEPS) showed 
the medical costs associated with RA were 22.3 billion ($2,085 per person).48 The 
resulting swollen and painful joints often lead to disabilities, diminished quality of life, 
and premature mortality.13 Cost-effective conventional diseases modifying anti-rheumatic 
drugs (DMARDs) have served as first-line therapy to relieve the symptoms. However, 
patients tend to develop tolerance and have diminished response over time. Switching to 
or additional biologic agents is recommended in the event of inadequate response to 
conventional DMARDs. Biologic DMARDs further divide into several classes: (1) tumor 
necrosis factor inhibitors (TNFi): adalimumab (ADA), certolizumab pegol (CTZ), 
etanercept (ETN), golimumab (GLB), and infliximab (IFX); (2) T-cell costimulatory 
modulato: abatacept (ABT); (3) recombinant human interleukin-1 (IL-1) receptor 
antagonist: anakinra (ANA); (4) B-cell-depleting monoclonal antibody: rituximab (RTX); 
(5) monoclonal antibody to the IL-6 receptor: tocilizumab (TCZ); and (6) janus kinase 
inhibitor: tofacitinib (TOF). All these drugs have undergone randomized clinical trials 
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against methotrexate for regulatory approval but there have been few head-to-head trials 
to compare the relative efficacy among them. 
Randomized clinical trial, the gold standard for evidence-based health decision-
making, commonly compares one therapeutic intervention with placebo or standard care. 
Even though a few clinical trials have involved more than one intervention, few studies 
have looked at more than two interventions. Driven by the need for relative treatment 
efficacy assessment, advanced methods have been developed to incorporate multiple 
interventions. Unlike standard meta-analysis, which can only incorporate trials of one 
intervention, network meta-analysis can incorporate clinical trials of multiple 
interventions and can estimate the relative efficacy between any pair of interventions. 
With a series of direct comparisons between a common comparator (placebo) and one or 
two interventions, biologic therapies can be indirectly compared. Bayesian network meta-
analysis can incorporate previous knowledge about the treatment effects in form of prior 
information of effect sizes and provide a posterior probability distribution for the effect 
size and its 95% credible interval (CrI).4,17 
The difference between clinical trials could also contribute to the effect size 
estimation. Study characteristics and patient demographics between clinical trials might 
differ and randomization does not hold across these studies.4,6,7 Potential treatment effect 
modifiers (study-level covariates) may be caused by patient characteristics, inclusion and 
exclusion criteria, study protocol development, study outcome measurement, and 
administrative agency requirement. Treatment effect modifiers could bias the results of 
indirect comparisons and alter the magnitude and direction of treatment effect 
estimation.7,8 There are several published network meta-analyses of biologics DMARDs 
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but few have examined the effects of study level covariates. Therefore, the present 
network meta-analysis was conducted in the Bayesian framework to compare the relative 
efficacy of biological DMARDs when used in combination with methotrexate (MTX). 
Materials and Methods 
Materials 
A systematic literature review was conducted to collect data from peer-reviewed 
journal articles. A pre-determined search strategy (see Appendix A) was used to search 
for qualifying clinical trials in PubMed electronic databases through January 1999 to 
December 2015. Identified studies were screened based on titles and abstracts followed 
by a full-text review on selected studies. The references of full-text reviewed studies were 
also examined for potential additions. 
Studies included had to meet the following inclusion criteria: (1) the study was a 
multisite randomized clinical trial for biologic therapies of interest; (2) the study was 
conducted in adult human rheumatoid arthritis patients; (3) the study outcome was 
measured with American College of Rheumatology (ACR) criteria at week 24. The 
following exclusion criteria were also applied: (1) the study population included patients 
of other inflammatory diseases such as juvenile arthritis, Crohn’s disease, or psoriatic 
arthritis; (2) the study patients did not receive background MTX; (3) the study did not 
report number of patients with a 50% or 70% improvement in ACR criteria (ACR50 or 
ACR70). 
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Study outcome data extracted was the number and percentage of responders to 
treatment based on the ACR criteria at week 24. Treatment outcomes measured in 
ACR20/50/70 were considered as separate datasets and evaluated respectively. Study 
characteristics including authorship, year of publication, and biologic intervention 
received were extracted from selected papers. Patient demographics including mean age, 
percentage of females, mean disease duration in years, swollen joint count (SJC), tender 
joint count (TJC), C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), 
and percentage of rheumatoid factor positive (RF+) were also extracted from selected 
papers. Means and standard errors were also extracted for continuous patient 
demographics if available. Data extracted for ESR and CRP were converted to the unit of 
mm/h and mg/L respectively if reported in other units. Study covariates were centered at 
their weighted means to make the results more interpretable.  
When other forms of summary data such as the geometric mean, median, range, 
or interquartile were reported, the arithmetic mean was calculated. Study covariates 
reported in geometric mean were considered missing. When a study reported the median 
(m), low and high end of the range (a and b), and sample size (n), the median was used as 
the the mean when n ≥ 25 and the mean was calculated by 𝑎+2𝑚+𝑏
4
 when n < 25.14,15 
When a study reported m, first and third interquartile (q1 and q3), and n, the mean was 
calculated by the average of m, q1, and q3 regardless of the sample size.14 Missing data in 
epidemiological and clinical research undermines the power and validity of clinical 
researches.49 The predictive mean matching approach was used to perform multiple 
imputation on missing values in covariates. Three imputed values were predicted for each 
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missing value for analysis and the results of the three imputed datasets were pooled for 
final treatment effect estimation. 
Model Selection 
There are several choices of models for network meta-analysis. The fixed-effects 
network meta-analysis model (FE model) which assumes homogeneity of effect sizes 
among selected studies was fit to the datasets first.  
The random-effects model (RE model) assumes that included studies are 
heterogeneous and the difference observed in effect sizes is not due to sampling error. RE 
model treats measured effect sizes and estimated model parameters as the random sample 
of the true population effect size and true model parameters.  
Then mixed-effects models (ME models) were used to investigate the sources of 
heterogeneity between included studies and the contribution to heterogeneity of included 
covariates. The ME model, also known as meta-regression, includes study-level treatment 
effect modifiers or covariates and can further evaluate their contribution to heterogeneity. 
The treatment effect modifier 𝑋𝑗 is incorporated in the model via the mean of the 
distribution of random-effects.  
Statistical Analysis 
Bayesian network meta-analysis models were used to estimate relative efficacy 
between biologic DMARDs.  In the Bayesian framework, model parameters are 
considered random variables. The prior probability distribution reflects prior beliefs 
about possible values of the parameters. The likelihood represents the probably 
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probability of the data as a function of the parameters. A posterior probability distribution 
of the parameter is obtained by combining the prior probability distribution and the 
likelihood. Network meta-analysis models usually have multiple parameters for effect 
size functions. The Monte Carlo method generates random sample values of the 
parameters from their posterior distributions and approximates all of these posterior 
quantities of interest to an arbitrary degree of precision. The empirical distribution 
provides a closer approximation to the true density as the number of repeated sample 
increases. For complicated multi-parametric models such as network meta-analysis, it is 
difficult to sample from the joint posterior distribution directly. In such cases, Gibbs 
sampler provides a computationally feasible alternative in which samples are drawn from 
the full conditional distributions of parameters. In this so-called Markov Chain, the 
algorithm will converge to the true distributions as the number of sampling goes to up 
towards infinity, By applying the same algorithm to the regular Monte Carlo 
approximation, the joint posterior distributions of the parameters could be approximated 
by this Markov Chain Monte Carlo (MCMC) method.  
No assumption was made for the treatment effect parameters, the heterogeneity 
parameter, and the covariate regression coefficients. The posterior distribution was 
estimated with non-informative priors to limit inference to collected data only. A uniform 
prior distribution (uniform [0, 2]) was used for the heterogeneity parameter σ in the 
random- and mixed-effects models. No prior distributions were assigned for the treatment 
effect parameters 𝑑𝐴𝑘 and the regression coefficients 𝛽𝐴𝑘 in the mixed-effect models. 
Rank probabilities were calculated for the treatment options for ACR20/50/70. 
The rank probability indicates the probabilities for each treatment to be the most, second, 
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third… the least efficacy treatment option. The treatments were ranked by their efficacy 
relative to placebo for each of the MCMC iterations. A frequency table based on these 
rankings was normalized by the number of iterations to calculate the rank probabilities.  
Heterogeneity was tested with the I² statistics, which describes the percentage of 
variation across studies. I² is an intuitive and simple expression of the heterogeneity of 
studies. The random-effects model was used if a significant variation in measured effect 
sizes among included studies was observed. In the mixed-effects model, I2 estimates the 
percentage of the unaccounted variability (residual heterogeneity plus sampling 
variability) attributed to residual heterogeneity. The Good Research Practice guideline of 
the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
suggested the following thresholds:  I² < 30% is considered mild heterogeneity, and I² > 
50% is considered notable heterogeneity.17 Discrepancy assessment of model fitness was 
conducted for goodness of fit. The deviance information criterion (DIC) is hierarchical 
model selection criteria and is particularly useful in Bayesian analysis. A smaller value of 
DIC indicates a better model fitness. 
All analyses were conducted using the statistical program R. R package gemtc 
(version 0.8, released March 1, 2016) was used for the Bayesian analysis. R package mice 
(version 2.24, released November 9, 2015) was used for multiple imputation. Bayesian 
software JAGS (Just Another Gibbs Sampler, version 4.2.0, released February 19, 2016)) 
was used for Gibbs sampling.  
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Results 
Systematic Review 
The search strategy identified 1,337 articles. After title and abstract review, 1,301 
studies were excluded for the following reasons: (1) the study was not conducted for the 
biologics of interest (n = 962); (2) the study was not a multisite randomized clinical trial 
(n = 242); (3) the study utilized different treatment outcome measurement (n = 63); (4) 
the study was not conducted in other population (n = 34). After full-text review, 16 
articles were further excluded due to the following reasons: (1) the patients were 
receiving other concomitant RA treatments other (n=10); (2) the study did not have 
background MTX in combination with the biologics (n=5); (3) the clinical trial for 
toficitanib, an oral biologic agent with different indication from other biologics (n=1).  
The 20 selected studies included a total of 7,666 patients that received biologic 
DMARDs for rheumatoid arthritis. Treatment arms were balanced within each study 
indicating sufficient randomization. Table 1 shows the study characteristics and patient 
demographics of each study, whereas Table 2 shows the numbers of responders and 
response rates for ACR20/50/70 criteria25-44. The evidence network is demonstrated in 
Figure 2. Each node represents a biologic therapy. Each edge between nodes represents a 
direct comparison and the width of the edges represents the number of clinical trials 
contributing to the comparison pair. Placebo was the common comparator among all 
included studies. Nineteen studies (95%) were two-armed clinical trials that compared 
one biologic therapy with placebo while one study (5%) was a three-armed trial that 
compared two biologics and placebo. For study covariates, three (15%) studies reported 
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the median for all patient demographic covariates, two (10%) studies reported the median 
for ESR and CRP and mean for other covariates, and two (10%) other studies report the 
geometric mean for also ESR and CRP. Baseline ESR, CRP, and RF+ were missing in 
the ten (50%), one (5%), and two (10%) studies, respectively. Imputed values were 
analyzed separately before pooling model estimations for interpretation. 
Network Meta-analysis Results 
Model results for estimated relative efficacy of biologic DMARDs are 
demonstrated in this section. ACR20/50/70 outcomes were analyzed respectively. This 
section summarizes and reports model results for ACR20 dataset. The ACR20 response 
rate ranged from 38.0% to 71.0% (Table 2). Notable heterogeneity was observed in the 
dataset (Fixed-effects model: I2 = 58%). The Random-effects model demonstrated an 
improvement in model fitness from the fixed-effects model but had similar DIC values 
when covariates were included (Appendix B). Therefore, the random-effects network 
meta-analysis model was used for the relative treatment effect estimation. All biologics 
except ANA demonstrated a statistically significant superiority over placebo, whereas 
ANA showed a statistically non-significant superiority over placebo (Figure 7). The rank 
probability (Figure 8) demonstrated the probabilities of each treatment to be the best to 
the least efficacious among the treatment options. ETN had the highest probability 
(42.6%) to be the most efficacious treatment. Followed by CTZ, which had similar 
probabilities for being the best and the second best (36.7% vs 35.5). Rank probabilities of 
each treatment are found in Table 13.  Effect of study covariates was estimated with 
mixed-effects models for each covariate. Duration of disease had the largest but not 
statistically significant impact among all covariates (OR=1.59, 95% CrI=0.71-3.48). 
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Female percentage (OR=1.27, 95% CrI=0.63-2.53), mean age (OR=1.27, 95% CrI=0.54-
3.11), TJC (OR=1.21, 95% CrI=0.52-2.91, and SJC (OR=1.20, 95% CrI=0.42-3.44) also 
had no significant impact on treatment effects. 
For the ACR50 criteria data, the response rate ranged from 17.0% to 55.2%. 
Notable heterogeneity was also observed in the dataset (Fixed-effects model: I2 = 51%). 
The same improvement in model fitness and reduction in I2 was observed in random-
effects model. The covariate duration of disease had a significant effect on treatment 
effect (OR=2.05. 95% CrI=1.05-3.71). Covariates mean age (OR=1.87, 95% CrI=0.79-
4.50), SJC (OR=1.61, 95% CrI=0.57-4.40), TJC (OR=1.40, 95% CrI=0.58-3.51), and 
female percentage (OR=0.92, 95% CrI=0.44-1.98) had no significant impact on treatment 
effects. Hence, the mixed-effects model with covariate duration of disease was used for 
the relative treatment effect estimation. The same treatment superiority over placebo was 
observed for all biologics except ANA (Figure 9). The rank probability for ACR50 
criteria (Figure 10) showed that ETN had the highest probability (57.6%) to be the best 
treatment option. CTZ had the highest probability for being the second best treatment 
(45.4%), and ANA (66.9%) had the highest probability to be the least efficacious 
biologic. Detailed rank probabilities of each treatment can be found in Table 14. 
This section summarizes and reports model results for ACR70 dataset. The 
ACR70 response rate ranged from 0% to 26.9%. Moderate heterogeneity was observed in 
the dataset (I2 = 43%). None of the study covariates had a significant impact on treatment 
effects. The random-effects model had the smallest DIC. Therefore, the random-effects 
model was used for treatment effect inference. In the ACR70 criteria data, all the 
biologics except for ANA and RTX demonstrated a statistically significant benefit over 
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placebo (Figure 11). The rank probability (Figure 12) showed that ETN had the highest 
probability (98.2%) to be the most superior treatment. The second best treatment for 
ACR70 dataset was TCZ (34.7%). RTX had the highest probability to be the least 
efficacious treatment (29.1%). Specific rank probabilities of each treatment can be found 
in Table 15. 
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Table 13. Rank Probabilities of Treatment Groups, ACR20 Dataset 
 
 
Table 14. Rank Probabilities of Treatment Groups, ACR50 Dataset 
 
 
 Table 15. Rank Probabilities of Treatment Groups,  ACR70 Dataset 
 
  
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th
ABT 0.12% 0.55% 1.58% 4.00% 7.94% 14.43% 22.37% 28.78% 19.98% 0.26%
ADA 2.63% 10.43% 20.27% 21.07% 19.42% 12.79% 7.87% 4.21% 1.31% 0.02%
ANA 1.97% 3.28% 4.85% 6.07% 7.28% 8.96% 11.27% 16.31% 30.15% 9.87%
CTZ 36.77% 35.48% 14.47% 6.79% 3.44% 1.83% 0.81% 0.34% 0.08% 0.00%
ETN 42.67% 18.66% 10.87% 7.78% 5.38% 4.31% 3.52% 3.27% 2.78% 0.79%
GLB 3.28% 7.30% 11.59% 13.21% 13.80% 14.13% 13.63% 12.19% 9.83% 1.05%
IFX 0.62% 2.54% 6.17% 10.49% 15.28% 19.99% 20.18% 16.02% 8.46% 0.26%
Placebo 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.07% 1.07% 13.41% 85.46%
RTX 8.03% 11.49% 13.80% 12.11% 11.69% 10.97% 10.28% 10.22% 9.29% 2.12%
TCZ 3.93% 10.27% 16.42% 18.49% 15.78% 12.60% 10.02% 7.60% 4.72% 0.18%
Probability being the nth ranked treatmentTreatment
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th
ABT 0.02% 0.27% 1.29% 3.93% 9.09% 17.88% 28.22% 33.12% 6.17% 0.02%
ADA 0.38% 2.27% 8.12% 16.02% 22.19% 20.62% 16.27% 12.28% 1.88% 0.00%
ANA 0.13% 0.35% 0.80% 1.07% 1.85% 2.73% 4.45% 10.03% 66.91% 11.69%
CTZ 27.65% 45.41% 17.73% 5.18% 2.38% 1.04% 0.37% 0.18% 0.06% 0.01%
ETN 57.64% 11.66% 7.94% 4.68% 3.34% 3.03% 3.28% 5.42% 2.49% 0.53%
GLB 10.67% 25.78% 29.61% 14.24% 7.91% 5.34% 3.30% 2.44% 0.70% 0.02%
IFX 0.23% 1.24% 4.53% 11.19% 18.18% 24.09% 23.39% 14.71% 2.43% 0.01%
Placebo 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.32% 12.48% 87.19%
RTX 1.87% 6.39% 11.76% 15.66% 14.70% 13.23% 12.98% 17.03% 5.86% 0.53%
TCZ 1.43% 6.64% 18.23% 28.03% 20.36% 12.04% 7.74% 4.49% 1.03% 0.02%
Probability being the nth ranked treatmentTreatment
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th
ABT 0.01% 0.61% 1.88% 4.36% 8.34% 15.54% 26.08% 29.21% 13.21% 0.76%
ADA 0.16% 12.68% 20.20% 22.96% 19.02% 12.25% 7.61% 3.82% 1.23% 0.08%
ANA 0.21% 7.10% 7.85% 8.05% 9.74% 11.67% 12.84% 17.18% 15.28% 10.08%
CTZ 0.23% 17.01% 18.64% 17.51% 14.96% 11.74% 9.60% 6.61% 2.97% 0.74%
ETN 98.15% 0.55% 0.23% 0.32% 0.14% 0.13% 0.15% 0.14% 0.17% 0.03%
GLB 0.50% 20.66% 16.07% 14.84% 13.83% 11.63% 9.49% 7.88% 4.18% 0.93%
IFX 0.10% 4.40% 8.11% 12.68% 17.29% 22.71% 19.01% 11.21% 4.18% 0.33%
Placebo 0.00% 0.00% 0.00% 0.00% 0.00% 0.05% 0.42% 4.51% 28.68% 66.35%
RTX 0.02% 2.20% 2.98% 4.20% 5.89% 7.38% 10.53% 17.18% 29.13% 20.49%
TCZ 0.63% 34.79% 24.04% 15.09% 10.79% 6.92% 4.27% 2.28% 0.99% 0.20%
Probability being the nth ranked treatmentTreatment
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Figure 7. Forest Plot of Treatment Effects, Bayesian RE Model, ACR20 Dataset 
  
Figure 8. Rank Probabilities Plot, Bayesian RE Model, ACR20 Dataset 
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Figure 9. Forest Plot of Treatment Effects, Bayesian ME Model with Duration of Disease, 
ACR50 Dataset 
 
Figure 10. Rank Probabilities Plot, Bayesian ME Model with Duration of Disease, 
ACR50 Dataset 
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Figure 11. Forest Plot of Treatment Effects, Bayesian RE Model, ACR70 Dataset 
 
 
Figure 12. Rank Probabilities Plot, Bayesian RE Model, ACR70 Dataset
 52 
 
Discussion 
The advantage of network meta-analysis is that it can compare multiple 
treatments via an evidence network and increase the precision of measurement by pooling 
effect sizes. However, in this study, the ACR70 dataset had a small number of 
responders, which led to less accurate treatment effect estimation.  The mean ACR70 
response rate was 10.0% among all study arms whereas the mean ACR50 and ACR20 
response rate were 23.6% and 44.3% respectively. The small sample sizes contributed to 
the less accurate treatment effect estimation and wide credible intervals in ACR70 
results. 
In addition, the ACR70 criteria were more stringent than those of ACR20 and 
ACR50. It required the patients to have at least a 70% improvement in the number of 
tender and swollen joints, and a 70% improvement in at least 3 of the following: (1) the 
patient’s global assessment of disease status; (2) the patient’s assessment of pain; (3) the 
patient’s assessment of function; (4) the physician’s global assessment of disease status; 
(5) serum C-reactive protein levels. These are the highest ACR criteria for effective 
treatment, which is difficult to achieve in 6 month of treatment. Four studies arms had no 
patients that reached this outcome.  
 Despite rigorous testing for effect size modifying covariate, duration of disease 
was the only study covariate to have statistically significant effect on treatment effect.  
This effect was not observed in the ACR20 or ACR70 data. The inclusion of study 
covariates did not have notable improvement on either DIC for model fitness or I2 
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statistic for heterogeneity assessment.  Therefore, the effect of duration of disease on 
treatment outcome in ACR50 data is most likely to be caused by chance alone.  
 The study is limited in several ways. First, the number of study and number of 
patients included was small. We included studies using placebo as the common 
comparator to minimize the bias inconsistency that additional studies might introduce. As 
a result, only 20 studies were included for the nine biologic products of interest. Second, 
pooling randomized clinical trials in a network meta-analysis is not the same as 
conducting a randomized controlled trial of the nine different drugs because 
randomization is compromised. Effects of a study-level covariate estimated in the mixed-
effects model might not represent the true effect of the study covariate at the patient level. 
In addition, this study only assessed ACR criteria at week 24. Information from clinical 
trials used different outcome measurement or measured treatment outcomes at different 
endpoint were not included in the analysis.  
Based on the network meta-analysis, we found that all biologics DMARDs were 
superior to placebo except for ANA in all datasets and RTX in ACR70 dataset. ETN was 
had the highest probability to be the best treatment in all three datasets. CTZ had the 
highest probability to be the second best option in ACR20 and ACR50 datasets, and TCZ 
held the second place in the ACR70 dataset. The rest of the rank probabilities vary by 
dataset but placebo was the lowest ranked option in all datasets. Therefore, despite the 
limitations of this study, the results are consistent with current knowledge that biologic 
DMARDs are superior to placebo and although more research remains to be done, ETN 
may be the most effective option for rheumatoid arthritis. 
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APPENDIX A 
SEARCH STRATEGY FOR SYSTEMATIC LITERATURE REVIEW 
The following search terms and MeSH (Medical Subject Headings) terms were used to 
identify eligible studies for this network meta-analysis: 
 
("Certolizumab Pegol" OR "Abatacept" OR "Infliximab" OR "Rituximab" OR 
"Adalimumab" OR "Etanercept" OR "golimumab" OR "tocilizumab" OR 
"tofacitinib")  
AND  
"Randomized Controlled Trial" [Publication Type]  
AND  
(ACR OR ACR20 OR “ACR 20” OR ACR50 OR “ACR50” OR ACR70 OR “ACR 
70” OR "American College of Rheumatology" OR "American College of 
Rheumatology 20% improvement criteria" OR "American College of Rheumatology 
50% improvement criteria" OR "American College of Rheumatology 70% 
improvement criteria")  
AND  
("24 weeks" OR “week 24” OR “week-24”) 
NOT  
"psoriatic arthritis" 
  
 55 
 
APPENDIX B 
MODEL FITNESS AND HETEROGENEITY 
This appendix presents model fitness and heterogeneity assessment of all models. The 
use of random-effects model (RE model) increased model fitness and alleviated 
unaccounted for heterogeneity compared with fixed-effects model (FE model) in all three 
datasets. The inclusion of study covariates did not have notable impact on either model 
fitness or heterogeneity among mixed-effects models (ME models). 
Table 16. Model Fitness and Heterogeneity Comparison, Bayesian Models 
 
 
  
Dataset Model DIC I^2
ACR20 FE model 123.66 58%
ME model with covariate age 80.96 4%
ME model with covariate duration of disease 80.87 4%
ME model with covariate SJC 80.68 4%
ME model with covariate RF+ 80.66 4%
ME model with covariate ESR 80.46 3%
RE model 80.45 3%
ME model with covariate CRP 80.42 4%
ME model with covariate female percentage 80.41 3%
ME model with covariate TJC 80.36 3%
ACR50 FE model 110.48 51%
ME model with covariate duration of disease 80.18 9%
ME model with covariate female percentage 80.00 4%
ME model with covariate SJC 79.54 4%
RE model 79.33 3%
ME model with covariate TJC 79.20 3%
ME model with covariate age 78.99 3%
ACR70 FE model 98.61 43%
ME model with covariate duration of disease 83.57 19%
ME model with covariate female percentage 83.14 14%
ME model with covariate SJC 82.55 16%
ME model with covariate age 81.58 12%
ME model with covariate TJC 81.35 12%
RE model 80.80 12%
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